Characteristics of Covid-19 in Patients With Multiple Sclerosis

Characteristics of Covid-19 in Patients With Multiple Sclerosis Publisher Pubmed

Ghadiri F¹ ; Sahraian MA¹ ; Shaygannejad V² ; Ashtari F² ; Ghalyanchi H³ ; Baghbanian SM⁴ ; Mojdehipanah H⁵ ; Majdinasab N⁶ ; Hosseini S⁷ ; Poursadeghfard M⁸ ; Beladimoghadam N⁹ ; Razazian N¹⁰ ; Ayoubi S¹ ; Rezaeimanesh N¹ Show All Authors

Ghadiri F¹
Sahraian MA¹
Shaygannejad V²
Ashtari F²
Ghalyanchi H³
Baghbanian SM⁴
Mojdehipanah H⁵
Majdinasab N⁶
Hosseini S⁷
Poursadeghfard M⁸
Beladimoghadam N⁹
Razazian N¹⁰
Ayoubi S¹
Rezaeimanesh N¹
Eskandarieh S¹
Naser Moghadasi A¹

Show Affiliations

1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Hassan Abad square, Tehran, Iran
2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3. Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran
4. Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran
5. Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran
6. Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7. Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
8. Department of Neurology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
9. Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
10. Department of Neurology, Medicine Faculty, Kermanshah University of Medical Sciences, Kermanshah, Iran

Source: Multiple Sclerosis and Related Disorders Published:2022

Abstract

Background: Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population. Methods: Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe. Results: A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003–5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41–6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms. Conclusion: The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity. © 2021 Elsevier B.V.

Related Docs

View other Related Docs

1. The Study of Covid-19 Infection Following Vaccination in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)

2. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)

3. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)

4. Association Between Disease-Modifying Therapies and Adverse Clinical Outcomes in Multiple Sclerosis Patients With Covid-19 Infection, Multiple Sclerosis and Related Disorders (2022)

5. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)

6. Evaluation of the Rate of Covid-19 Infection, Hospitalization and Death Among Iranian Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2020)

7. Coronavirus Disease 2019 (Covid-19) in Pediatric Patients With Autoimmune Disorders, European Journal of Pediatrics (2023)

8. Covid-19 Among Patients With Multiple Sclerosis a Systematic Review, Neurology: Neuroimmunology and NeuroInflammation (2021)

Experts (# of related papers)

View all Related Experts

Mohammad Ali Sahraian (21)

Sharareh Eskandarieh (11)

Style	Citing Format
MLA	Ghadiri F, et al.. "Characteristics of Covid-19 in Patients With Multiple Sclerosis." Multiple Sclerosis and Related Disorders, vol. 57, no. , 2022, pp. -.
APA	Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi H, Baghbanian SM, Mojdehipanah H, Majdinasab N, Hosseini S, Poursadeghfard M, Beladimoghadam N, Razazian N, Ayoubi S, Rezaeimanesh N, Eskandarieh S, Naser Moghadasi A (2022). Characteristics of Covid-19 in Patients With Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 57(), -.
Chicago	Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi H, Baghbanian SM, Mojdehipanah H, et al.. "Characteristics of Covid-19 in Patients With Multiple Sclerosis." Multiple Sclerosis and Related Disorders 57, no. (2022): -.
Harvard	Ghadiri F et al. (2022) 'Characteristics of Covid-19 in Patients With Multiple Sclerosis', Multiple Sclerosis and Related Disorders, 57(), pp. -.
Vancouver	Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi H, Baghbanian SM, et al.. Characteristics of Covid-19 in Patients With Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 2022;57():-.
BibTex	@article{ author = {Ghadiri F and Sahraian MA and Shaygannejad V and Ashtari F and Ghalyanchi H and Baghbanian SM and Mojdehipanah H and Majdinasab N and Hosseini S and Poursadeghfard M and Beladimoghadam N and Razazian N and Ayoubi S and Rezaeimanesh N and Eskandarieh S and Naser Moghadasi A}, title = {Characteristics of Covid-19 in Patients With Multiple Sclerosis}, journal = {Multiple Sclerosis and Related Disorders}, volume = {57}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Ghadiri F AU - Sahraian MA AU - Shaygannejad V AU - Ashtari F AU - Ghalyanchi H AU - Baghbanian SM AU - Mojdehipanah H AU - Majdinasab N AU - Hosseini S AU - Poursadeghfard M AU - Beladimoghadam N AU - Razazian N AU - Ayoubi S AU - Rezaeimanesh N AU - Eskandarieh S AU - Naser Moghadasi A TI - Characteristics of Covid-19 in Patients With Multiple Sclerosis JO - Multiple Sclerosis and Related Disorders VL - 57 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract